suggests that protein aggregates and/or inclusions are true aging factors in the yeast model system. Because the beneficial functions of Mca1 related to aggregate management and longevity are only partially dependent on the catalytic cysteine C276, it is conceivable that under some conditions, metacaspase-dependent PCD activities (6-8) may be balanced by both metacaspase-dependent and independent proteostasis. In addition, the data raise the possibility that caspases and/or metacaspases originally evolved as PQC-related cytoprotective factors that were later adopted as PCD-related executioners, perhaps upon their overinduction during severe stress. Elucidating the nature of the environmental cues regulating the switching of metacaspase functions between proteostasis and PCD might explain how decisions concerning survival are made at the level of the individual cell versus the cell community.
pRS423-Cup1-Rnq1-mRFP plasmid, E. Deuerling for the Mca1 antibody, C. Andréasson and U. Hartl Stochastic fluctuations are inherent to gene expression and can drive cell-fate specification. We used such fluctuations to modulate reactivation of HIV from latency-a quiescent state that is a major barrier to an HIV cure. By screening a diverse library of bioactive small molecules, we identified more than 80 compounds that modulated HIV gene-expression fluctuations (i.e., "noise"), without changing mean expression. These noise-modulating compounds would be neglected in conventional screens, and yet, they synergized with conventional transcriptional activators. Noise enhancers reactivated latent cells significantly better than existing best-in-class reactivation drug combinations (and with reduced off-target cytotoxicity), whereas noise suppressors stabilized latency. Noise-modulating chemicals may provide novel probes for the physiological consequences of noise and an unexplored axis for drug discovery, allowing enhanced control over diverse cell-fate decisions.
F rom infectious disease to stem cells and cancer, therapeutic manipulation of cell fate remains a fundamental goal. Efficient manipulation has proven difficult, in part, because cell-fate decisions are often regulated by stochastic cellular processes (1-4) that generate heterogeneity in signaling responses and result in substantial cell-to-cell variability. For pathogens that establish persistent states (e.g., HIV latency), therapeutic targeting and perturbation of the dormant-cell phenotype has proven exceptionally challenging.
HIV can enter a long-lived proviral latent state (Fig. 1A) that is a leading obstacle to a cure (5) and requires that infected individuals remain on lifelong antiretroviral therapy. A leading HIVcure strategy attempts to stimulate the latent virus back into an active-replication state and simultaneously eliminate it by antiretroviral therapy (6). However, efficient reactivation of latent HIV has had limited success (7), perhaps because of the stochastic nature of latency (8) (9) (10) (11) .
Small-molecule compounds that promote HIV reactivation have been identified, primarily from reporter assays that detect amplification of the mean level of HIV gene expression (12) , but these compounds fall short of completely reactivating latency (10) . However, given the stochastic nature of gene expression (13) , the mean represents only one aspect of expression. We examined whether compounds that affect fluctuations around the mean gene-expression level (i.e., "noise") synergize with existing drug candidates.
Noise in gene expression often results from promoter transitions between on and off states that generate episodic "bursts" of transcription (13) (14) (15) (16) (17) . In this "two-state" model, RNA polymerase II stalls on the HIV long terminal repeat (LTR) promoter (18, 19) , but when the elongation stall is relieved, multiple polymerases can read through, which results in a burst of transcripts and highly variable expression levels (Fig. 1A,  inset) . If HIV expression reaches sufficient levels, HIV's autoregulatory gene products (i.e., Tat and Rev) drive reactivation and ultimately active replication. Transcriptional activators, such as tumor necrosis factor (TNF), typically activate the LTR by increasing transcriptional initiation, thereby increasing the frequency of transcriptional events (18, 19) (Fig. 1B) . In contrast, compounds that modulate elongation increase the duration in the on state, thereby increasing the transcriptional "burst size" and amplifying noise (20) . Stochastic simulations showed that combining activators with noise enhancers generates a synergistic effect, increasing expression into the active replication regime (Fig. 1B) . A convenient method to measure this synergy is to plot noise magnitude (the variance over the mean squared or coefficient of variation squared CV 2 ) versus mean expression (Fig. 1C) . Activators, which increase burst frequency, are constrained to increasing expression along negatively sloped lines of constant burst size on these noise-versusmean plots (18, 19) . In contrast, amplification of noise-which increases the burst size-transfers the system to a new diagonal line of greater burst size where each burst generates more gene product; so, an equivalent increase in burst frequency generates higher amounts of mean expression and substantially more reactivation (Fig. 1D) . We tested this theory by searching for noise-enhancing compounds that might synergize with conventional transcriptional activators to enhance HIV reactivation from latency.
To identify noise-enhancing compounds, we screened (21) a diverse library of 1600 bioactive small molecules in an isoclonal Jurkat cell line that exhibits a well-characterized noise-versusmean expression profile (18, 19) . This Jurkat T cell line contains one integrated copy of the HIV LTR promoter expressing a short-lived green fluorescent protein (GFP) reporter (d 2 GFP)-the short GFP half-life focuses the screen toward identifying compounds that modulate transcription. Flow cytometry analysis identified more than 100 compounds that enhanced GFP-expression noise (CV 2 ) by > 2s, without considerably altering mean-GFP expression ( Fig. 2A) . These noise-enhancer compounds would be neglected in conventional transcriptional activator screens, which only examine the mean GFP axis.
To find noise-enhancer compounds that might synergize with activators, we next identified which compounds were transcriptional modulators using a stable mCherry reporter driven off a second LTR integration (fig. S1 ). The differential stability of mCherry and d 2 GFP allowed us to select compounds that enhanced transcriptional noise (21) . This two-reporter assay filtered out 25 compounds, leaving 85 transcriptional noise-enhancer compounds (Fig. 2B and table S1 ). To ensure that the observed noise enhancement was not an artifact of a specific HIV-integration site, we used a single-cell microscopy approach (19) and observed noise enhancement across a broad spectrum of HIV-integration sites ( fig. S2 and movie S1).
It was intriguing that previously known latency modulators act as noise enhancers (table  S2) . Previous analysis showed that chromatin remodelers [histone deacetylase (HDAC) inhibitors, methylation inhibitors, and bromodomain inhibitors] synergize with transcriptional activators [TNF, phorbol 12-myristate 13-acetate (PMA), and prostratin] to enhance HIV reactivation; e.g., the HDAC inhibitor (HDACi) suberanilohydroxamic acid (SAHA) synergizes with prostratin and TNF (20, 22) . Chromatin remodeling compounds were found to cause modest increases in noise, whereas known transcriptional activators primarily increased mean expression (Fig. 2C) . This observation-that previously identified synergies between TNF or prostratin and HDACi's consist of a noise enhancer and an activator-supports the hypothesis that noise amplification may provide a generalized signature for compounds that synergize.
To test if the 85 newly identified noise enhancers synergized with transcriptional activators to enhance reactivation, we used a well-studied latency model in Jurkat cells (23) . These cells contain a single, integrated copy of a full-length, latent HIV genome that encodes a GFP reporter (21) . Upon stimulation with activators, a fraction of the latent cells reactivate, express GFP, and produce viral particles. We quantified synergy with the Bliss Independence Score (21), a threshold for strict additivity in the combination of two compounds. Despite noise-enhancer compounds not inducing reactivation on their own, pairwise Bliss scores show that >75% of compounds (64 of 85) significantly synergize with TNF (P < 0.0001) (Fig. 3A) . Similar amounts of synergy were observed in combinations with prostratin (~64%), with some noise enhancers doubling the reactivation efficacy of TNF and prostratin (Fig. 3A) . Noise enhancers tested on two alternate latency cell lines exhibited comparable synergies ( fig. S3 ), which confirms that the observed synergy is not specific to a single HIV integration site.
Theory predicts that the magnitude of noise enhancement should forecast the degree of reactivation synergy (21) . In agreement, the data exhibited a positive correlation between noise enhancement and reactivation (Fig. 3B) and larger increases in mean expression when noise enhancers and activators were combined (Fig. 3C and  fig. S4 ). To exclude that observed synergies resulted from nonspecific bioactivity of the compounds, we tested combinations of noise enhancers among themselves ( fig. S5 ) and in combination with HDAC and methylation inhibitors ( fig. S6) . None of these combinations yielded reactivation synergy. Moreover, when two random arrays of~80 nonenhancers of noise were tested for synergy with TNF and prostratin ( fig. S7 ), only~6.4% synergized with TNF and 2.6% synergized with prostratin. Importantly, "extrinsic" variability (e.g., cellular microenvironments) did not predict synergy ( fig. S8) . Thus, noise enhancement is a good predictor of synergy with transcriptional activators.
To test whether reactivation could be further optimized, we varied the doses of noise enhancer and activator ( fig. S9 ). The dose-response matrix for TNF or prostratin with cetirizine hydrochloride (noise enhancer V11) exhibited a peak in HIV reactivation at 25 mM V11 (table S2) and achieved greater reactivation than was caused by TNF or prostratin alone (Fig. 4A and fig. S10 ). Moreover, noise-enhancer cocktails exhibited substantially less off-target cytotoxicity than did other reactivation cocktails. We compared leading reactivation cocktails to 21 combinations of a noise enhancer with TNF + prostratin (Fig. 4B) , and all noise-enhancing cocktails increased reactivation by~150 to 200% over TNF + prostratin, with minimal cytotoxicity compared with SAHA-a leading candidate that enhances reactivation (7) but generates substantial off-target cytotoxicity for uninfected cells ( fig. S11) (21) .
In a primary T cell model of HIV latency (24) , >60% of noise enhancers tested synergized with PMA (Fig. 4C) , with some compounds reactivating half of the remaining cells that PMA alone did not reactivate (e.g., mebendazole, V7). Moreover, in both Jurkat and primary T cell models, noise suppression with manidipine hydrochloride, or S1, substantially reduced latent reactivation, as predicted from theory (Fig. 4, D and E) . Although there may be considerable technical challenge in identifying noise suppressors-due to the extrinsic noise threshold (4)-noise suppression could ultimately be used in strategies to limit spontaneous reactivation of latent HIV, stabilize other fate-specification processes, or identify antagonistic drug combinations.
Overall, the noise-modulating compounds are previously approved by the U.S. Food and Drug Administration and span diverse chemical classes and mechanisms of action [tables S1, S2, and (21)]. Although the effects of a single round of reactivation were incomplete (with about 50% of remaining latent cells responding for the best enhancers in primary T cells), latency-reversing strategies will likely require multiple rounds of treatment (10) and noise-enhancing compounds may allow each round of treatment to be more effective by including drugs with highly diverse mechanisms of action and nonoverlapping toxicities. Moreover, we identified these compounds in a fairly small screen of~1600 compounds; a more extensive screen might identify compounds that work better to allow multiple rounds of reactivation to eliminate the virus. For fundamental cell-biology research on the roles of noise (e.g., in cell-fate specification), noise-modulating chemicals could provide an approach to complement existing genetic noise-perturbation methods (25) (26) (27) (28) . From a pharmaceutical science and drugscreening perspective, "noise screening" presents an orthogonal axis to detect synergistic drug combinations. Compared with random synergy screening, noise screening requires substantially fewer tests. Blind synergy searches for pairwise combinations of N compounds require~N 2 tests; by contrast, noise screening permits~N tests. Noise screening might help identify compounds for manipulating other fate-switching phenotypes such as cellular reprogramming, metastasis, and bacterial persistence.
